NASDAQ: VERU
Healthcare · Biotechnology
Market Cap
$35.47M
52w High
$7.40
52w Low
$2.06
P/E
-2.35
Volume
65.47K
Outstanding Shares
16.05M
Price vs Fundamentals
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
The stock fell 56.67% over the last year. Revenue declined 98.32% over the trailing twelve months. Operating margin moved from -266.39% to -8,065.09%. Free cash flow grew 8.38% over the trailing twelve months.
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
Operating margin stands at -8,065.09%. Revenue declined 98.32% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
Valuation
Stock splits
Every 10 shares became 1
Profitability & growth
Analyst consensus
5
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.29 · Revenue est $1.9M
View